Bold Moves

Win the digital race in pharma

Unleash the power of our people

Pfizer announced key data and regulatory milestones for abrocitinib

In 2020, Pfizer took several important steps toward a potential option for people with moderate to severe atopic dermatitis by delivering on key data and regulatory milestones for abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor.

Through a robust Phase 3 clinical trial program, abrocitinib has demonstrated statistically superior improvements in skin clearance, disease extent and severity, as well as rapid improvements in itch versus placebo. Without relief, atopic dermatitis can have a debilitating impact on daily life for patients.

Five announcements around our clinical trial program recently showcased these data results, progressing toward possible regulatory decisions in 2021 (the outcome of which remains subject to regulatory review and labeling discussions):

  1. March 18: Positive JADE COMPARE top-line results highlighted the effect of two doses of abrocitinib in patients on background topical therapy. The study also included an active control arm with dupilumab.
  2. June 3: Complete results from JADE MONO-2, the second from a pair of replicate studies that evaluated two doses of abrocitinib monotherapy, reinforced the strong results from JADE MONO-1.
  3. June 10: Positive results from JADE TEEN demonstrated the efficacy and safety profile of abrocitinib in patients 12 to less than 18 years old.
  4. October 27: The U.S. Food and Drug Administration accepted for filing and granted priority review designation to abrocitinib, while the European Medicines Agency accepted the marketing authorization application.
  5. November 11: Positive top-line results from JADE REGIMEN, which evaluated two doses of abrocitinib following response to initial open label induction treatment with abrocitinib 200mg.

Key data and regulatory announcements for abrocitinib

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories